10-year follow-up of two phase 3 trials in relapsing MS (n=1656): continuous ocrelizumab vs starting it after 2 years of interferon beta-1a lowered 48-week confirmed disability progression (HR 0.76; 95% CI 0.61-0.95). Adverse events did not rise in the extension.
RCTn = 1,656
Hauser et al. Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Trials